• Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in Japan

• Matrix-M adjuvant to be supplied from Novavax

• Government of Japan will provide funding to Takeda for technology transfer, establishment of infrastructure and scale-up of manufacturing

• Adds to Takeda’s ongoing support of influenza pandemic preparedness in Japan

GAITHERSBURG, Md. & OSAKA, Japan-Saturday 8 August 2020 [ AETOS Wire ]

(BUSINESS WIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparti ... Read more »